Institutional Investors Are Betting On Theravance Biopharma (NASDAQ:TBPH)

June 15, 2018 - By Henry Gaston

Theravance Biopharma, Inc. (NASDAQ:TBPH) Logo

Sentiment for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH) institutional sentiment increased to 1.35 in Q1 2018. Its up 0.04, from 1.31 in 2017Q4. The ratio increased, as 42 funds increased and opened new stock positions, while 31 reduced and sold their stakes in Theravance Biopharma. The funds in our partner’s database now hold: 35.61 million shares, up from 35.06 million shares in 2017Q4. Also, the number of funds holding Theravance Biopharma in their top 10 stock positions decreased from 1 to 0 for a decrease of 1. Sold All: 6 Reduced: 25 Increased: 28 New Position: 14.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.31 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

The stock decreased 1.48% or $0.36 during the last trading session, reaching $23.93. About 59,434 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has declined 36.55% since June 15, 2017 and is downtrending. It has underperformed by 49.12% the S&P500.

Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on August, 14. They expect $-1.24 EPS, up 2.36 % or $0.03 from last year’s $-1.27 per share. After $-1.22 actual EPS reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts 1.64 % negative EPS growth.

Foundation Asset Management Lp holds 3.59% of its portfolio in Theravance Biopharma, Inc. for 399,537 shares. Baupost Group Llc Ma owns 9.31 million shares or 2.18% of their US portfolio. Moreover, Old West Investment Management Llc has 1.53% invested in the company for 109,320 shares. The New York-based Senzar Asset Management Llc has invested 1.44% in the stock. Rock Springs Capital Management Lp, a Maryland-based fund reported 652,600 shares.

Since January 1, 0001, it had 1 insider buy, and 2 sales for $556,864 activity.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

Ratings analysis reveals 100% of Theravance Biopharma’s analysts are positive. Out of 3 Wall Street analysts rating Theravance Biopharma, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $4500 while the high is $55.0. The stock’s average target of $49.33 is 106.14% above today’s ($23.93) share price. TBPH was included in 4 notes of analysts from February 8, 2018. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, February 27. Piper Jaffray initiated the stock with “Buy” rating in Thursday, March 29 report. Leerink Swann maintained Theravance Biopharma, Inc. (NASDAQ:TBPH) rating on Thursday, February 8. Leerink Swann has “Outperform” rating and $48 target. The company was maintained on Tuesday, May 8 by Cantor Fitzgerald.

More news for Theravance Biopharma, Inc. (NASDAQ:TBPH) were recently published by: Prnewswire.com, which released: “Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018” on June 06, 2018. Benzinga.com‘s article titled: “Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching” and published on May 19, 2018 is yet another important article.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: